Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer

American Journal of Health-System Pharmacy

Volumn 68, Issue 18, 2011, Pages 1699-1706

  Glück, Stefan ^a   Gorouhi, Fariborz ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Anastrozole; Antineoplastic agents; Aromatase inhibitors; Breast neoplasms; Exemestane; Letrozole; Mechanism of action; Pharmacoeconomics; Postmenopause; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FRACTURE; HEALTH CARE SYSTEM; HUMAN; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW;

EID: 80053072192     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100492     Document Type: Review

References (45)

1. American Cancer Society. Global cancer: facts and figures, 2nd ed. www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/ acspc-027766.pdf (accessed 2011 May 30).
2. Harris JR, Lippman ME, Morrow M et al. Diseases of the breast. Philadelphia, PA: Lippincott Williams & Wilkins; 2000.
3. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60:277-300.
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Breast cancer. V2. 2011.
5. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann Oncol. 2009; 20:1319-29.
6. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005; 23:619-29. (Pubitemid 46224240)
7. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365:1687-717.
8. Burstein HJ, Prestrud AA, Seidenfeld J et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010; 28:3784-96.
9. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007; 369:559-70.
10. Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008; 9:45-53.
11. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women withendocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005; 366:455-62. (Pubitemid 41111693)
12. Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009; 361:766-76.
13. Rea D, Hasenburg A, Seynaeve C et al. Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for five years: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormonesensitive early breast cancer. Cancer Res. 2010; 69:24. Abstract.
14. Food and Drug Administration. Guidance for industry. Clinical trial endpoints for the approval of cancer drugs and biologics. www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071590.pdf (accessed 2010 Dec 1).
15. Gluck S. The prevention and management of distant metastases in women with breast cancer. Cancer Invest. 2007; 25:6-13. (Pubitemid 46423584)
16. Rugo HS. The importance of distant metastases in hormone-sensitive breast cancer. Breast. 2008; 17:S3-8. (Pubitemid 351223529)
17. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003; 21:1431-9. (Pubitemid 46594092)
18. Mansell J, Monypenny IJ, Skene AI et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2009; 117:91-8.
19. Doughty J, Mansell J, Monypenny I. Distant recurrence and subsequent mortality in breast cancer patients treated at 5 UK centres. Breast. 2009; 18(suppl):S66. Abstract.
20. Le MG, Arriagada R, Spielmann M et al. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer. 2002; 94:2813-20. (Pubitemid 34547678)
21. Lamerato L, Havstad S, Gandhi S et al. Breast cancer recurrence and related mortality in US patients with early breast cancer. J Clin Oncol. 2005; 23:16s. Abstract.
22. Wiederkehr D, Kaura S, Mody-Patel N et al. Cost associated with distant, contralateral and locoregional breast cancer recurrence in a vertically integrated health care system, Paper presented at 6th European Breast Cancer Conference. Berlin, Germany; 2008 Apr.
23. Jones SE, Seyanaeve C, Hasenburg A et al. Results from the first planned analysis of the TEAM (Tamoxifen Exemestane Adjuvant Multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Res. 2009; 69:2. Abstract.
24. Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359:2131-9. (Pubitemid 34694019)
25. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365:60-2.
26. Thurlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005; 353:2747-57. (Pubitemid 43016814)
27. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350:1081-92. (Pubitemid 38298988)
28. Jonat W, Gnant M, Boccardo F et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006; 7:991-6. (Pubitemid 44804137)
29. Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al. Appendix: letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009; 361:766-76.
30. Regan MM, Colleoni M, Giobbie-Hurder A et al. Adjusting for selective crossover in analyses of letrozole versus tamoxifen in the BIG 1-98 trial. Cancer Res. 2009; 69:24. Abstract.
31. Rugo H, Kaura S, Dranitsaris G. The number needed to treat to save a life: a comparison between aromatase inhibitors. Paper presented at 11th St. Gallen Oncology Conference. St. Gallen, Switzerland; 2009 Mar.
32. ClinicalTrials.gov. Comparison trial of letrozole to anastrozole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer (FACE). www.clinicaltrials.gov/ct2/show/NCT00248170 (accessed 2011 Jun 22).
33. Hind D, Ward S, De Nigris E et al. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007; 11:iii-iv, ix-xi,1-134.
34. Risebrough NA, Verma S, Trudeau M et al. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. Cancer. 2007; 110:499-508. (Pubitemid 47106137)
35. Mansel R, Locker G, Fallowfield L et al. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. Br J Cancer. 2007; 97:152-61. (Pubitemid 47057463)
36. Delea TE, Karnon J, Sofrygin O et al. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer. 2007; 7:608-18. (Pubitemid 47025818)
37. Delea TE, El-Ouagari K, Karnon J et al. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat. 2008; 108:375-87. (Pubitemid 351431071)
38. Lamerato L, Havstad S, Gandhi S et al. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer. 2006; 106:1875-82. (Pubitemid 43673201)
39. Karnon J, Delea T, Barghout V. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in post-menopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ. 2008; 9:171-83. (Pubitemid 351535306)
40. Eichler HG, Kong SX, Gerth WC et al. Use of cost-effectiveness analysis in healthcare resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004; 7:518-28. (Pubitemid 39390832)
41. Rocchi A, Verma S. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Support Care Cancer. 2006; 14:917-27.
42. Thompson D, Taylor DC, Montoya EL et al. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health. 2007; 10:367-76. (Pubitemid 47485660)
43. Locker GY, Mansel R, Cella D et al. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat. 2007; 106:229-38. (Pubitemid 350045007)
44. Karnon J, Kaura S. A survival based cost-effectiveness analysis of 5 years letrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer: 76-month update of BIG 1-98. J Clin Oncol. 2009; 27:15s. Abstract.
45. Karnon J, Kaura S. Updated survival-based analysis using inverse probability of censoring weighted analysis (IPCW) to estimate the cost-effectiveness of letrozole and anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer. J Clin Oncol. 2010; 28:15s. Abstract.